Introduction {#Sec1}
============

In our recently published article \[[@CR1]\], we reported that cardiovascular magnetic resonance (CMR) derived left atrial ejection fraction (LAEF) measured from the biplane method was lower in a well characterized cohort of heart failure with preserved ejection fraction (HFpEF) compared to healthy controls and was also independently associated with adverse outcomes. Furthermore, CMR biplane LAEF had excellent reproducibility. However, volumetric assessment of left atrial volumes (and hence function) derived from the short-axis (Simpson's short-axis \[SAX\]) method is widely recognised as the imaging gold standard \[[@CR2], [@CR3]\]. In a recent study of HFpEF patients, the biplane method was shown to have good correlation and agreements for LA volumetric analysis compared to the SAX method \[[@CR4]\]. However, no prior CMR studies in HFpEF have compared LAEF between both methods. Furthermore, the prognostic role of SAX LAEF in HFpEF has not been reported. We aimed to assess the agreements of both methods for LAEF (and LA volumes) utilising CMR in HFpEF. We also evaluated whether SAX LAEF is also related to clinical outcomes, in order to validate and strengthen our previous findings implicating CMR LAEF as a prognostic biomarker in HFpEF.

Methods {#Sec2}
=======

From our original study cohorts \[[@CR1]\] of HFpEF (n = 140) and healthy controls (n = 48), paired data for image analysis of both CMR biplane and SAX LAEF derivation was available in 136 subjects (HFpEF n = 97, controls n = 39). HFpEF was defined as clinical or radiographic evidence of heart failure and left ventricular ejection fraction \> 50%. Exclusion criteria for HFpEF included: myocardial infarction in the preceding 6 months, suspected or confirmed cardiomyopathy or constrictive pericarditis, non-cardiovascular life expectancy \< 6 months, severe chronic obstructive pulmonary disease (or forced expiratory volume \[FEV~1~\] \< 30% predicted or forced vital capacity \[FVC\] \< 50% predicted), severe native valve disease and significant renal impairment (estimated glomerular filtration rate \[eGFR\] \< 30 ml/min. The control population were age- and sex-matched compared to HFpEF and asymptomatic. As previously reported, hypertensive controls were also included since hypertension is highly prevalent in this age group of patients. Furthermore, hypertension is intimately linked with HFpEF development and is also reportedly associated with LA dysfunction \[[@CR5]\] and we wanted to account for this potential confounder.

Study recruitment, blood sampling, six-minute walk testing, imaging protocols and analytical methods for CMR have been detailed previously. For the SAX method (see Fig. [1](#Fig1){ref-type="fig"}), a contiguous stack of short-axis steady-state-free-precession images were acquired with retrospective ECG gating (or prospective gating in subjects with AF). Both end-diastolic and end-systolic frames were contoured to derive maximal left atrial volume \[LAV max\] and minimal left atrial volume (LAV min) and LAEF was calculated. Unlike the biplane method (see Fig. [2](#Fig2){ref-type="fig"}), SAX volumes were inclusive of the LA appendage but both techniques excluded pulmonary veins. The primary endpoint remained the composite of all-cause mortality or first HF hospitalization. Parameters with univariable association with the composite endpoint at p \< 0.1 was entered into Cox proportional hazards regression analysis. In cases of collinearity, variables with historically stronger prognostic importance from published literature were chosen for inclusion in Cox regression analysis and underwent stepwise elimination. Four separate clinically relevant Cox regression models were generated including a final model incorporating the strongest predictors. Cox regression models were limited to no more than 4 parameters (plus LAEF), allowing for approximately one parameter per 10 composite events. To allow hazard ratios (HR) to be compared according to one standard deviation increase, continuous predictor variables were Z-standardized. Event rates were calculated from Kaplan--Meier analysis. The Log-Rank test was used to detect differences in survival curves. In order to further assess the strength of both biplane and SAX LAEF in predicting outcomes, receiver operator characteristics (ROC) analyses were also performed.Fig. 1Biplane method. Cine 2- (**a**) and 4-chamber (**b**) images illustrating contoured (yellow) left atrial areas for volume (and ejection fraction) derivation excluding the left atrial appendage and pulmonary veins; *LAA* left atrial appendage; *LSPV* left superior pulmonary vein; *RIPV* right inferior pulmonary veinFig. 2Simpson's short-axis method. Short-axis cine stack of images illustrating contoured (yellow) left atrial areas for volume (and ejection fraction) derivation inclusive of the left atrial appendage but excluding the pulmonary veins. *LAA* left atrial appendage, *LSPV* left superior pulmonary vein; *LIPV* left inferior pulmonary vein

Inter-technique comparison of both LAEF derivation methods included paired t-testing, regression and the Bland--Altman method. Ten randomly selected subjects were chosen to undergo intra-observer evaluation for both techniques, a minimum of 4 weeks apart. The two-way mixed-effect intraclass correlation co-efficient (ICC), coefficient of variation (COV) and Bland--Altman analysis were used for test intra-observer agreements.

Results {#Sec3}
=======

Baseline clinical and imaging characteristics are shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Both HFpEF and controls remained evenly matched for age (73 ± 8) and gender. HFpEF was associated with a high burden of co-morbidities including hypertension, diabetes, anaemia and renal dysfunction. Atrial fibrillation (AF) was noted in 24% of HFpEF. Compared to controls, HFpEF was characterised by lower exercise capacity, worse diastolic function (LA volumes, left ventricular mass, B-type natriuretic peptide \[BNP\] and N-terminal pro-atrial natriuretic peptide \[NT-proANP\]), more prevalent focal (late gadolinium enhancement imaging) and diffuse fibrosis (extracellular volume and indexed extracellular volume \[iECV\]); p \< 0.05 for all. Feasibility of image analysis for LA measures by both techniques was 100% in all subjects. With both methods, HFpEF patients had lower LAEF (biplane 34 ± 16; SAX 34 ± 13) compared to controls: overall (biplane 51 ± 11, SAX 47 ± 8), with hypertension (biplane 48 ± 12, SAX 45 ± 9) and without hypertension (biplane 52 ± 9, SAX 49 ± 7); p \< 0.0001 for all. No significant differences in LAEF were noted between hypertensive and non-hypertensive controls (biplane p = 0.222, SAX p = 0.119). Irrespective of methodology and cardiac rhythm, HFpEF was characterised by significantly higher LA volumes compared to controls (p \< 0.0001). HFpEF patients in AF had higher LA volumes and lower LAEF compared to sinus rhythm (p \< 0.0001).Table 1Baseline clinical characteristicsHFpEF\
n = 97Controls\
n = 39P valueDemographics Age (years)72 ± 1073 ± 50.486 Male (%)52 (54)18 (46)0.682Clinical Heart rate (beats per minute)71 ± 1468 ± 100.133 Systolic blood pressure (mmHg)145 ± 23151 ± 240.155 Diastolic blood pressure (mmHg)74 ± 1279 ± 100.012 Body mass index (kg/m^2^)34 ± 825 ± 3 \< 0.0001 Atrial fibrillation (%)23 (24)0 (0) \< 0.0001 Prior HF hospitalization (%)62 (64)0 (0) \< 0.0001 Diabetes (%)55 (57)0 (0) \< 0.0001 Hypertension (%)89 (92)19 (49) \< 0.0001 Angina (%)15 (16)0 (0)0.004 Known myocardial infarction (%)12 (12)0 (0)0.011 Asthma or COPD (%)14 (14)3 (8)0.149 TIA or CVA (%)12 (12)0 (0)0.011Functional status NYHA III/IV (%)23 (24)NA-- 6MWT distance (m)190 (130--275)380 (340--440) \< 0.0001 MLHF score49 (24--65)NA--Medications Betablocker (%)67 (69)2 (5) \< 0.0001 ACEi or ARB (%)86 (89)9 (23) \< 0.0001 Aldosterone antagonist (%)30 (31)0 (0) \< 0.0001 Loop diuretic (%)77 (79)0 (0) \< 0.0001Laboratory indices Urea (mmol/L)9 ± 46 ± 1 \< 0.0001 Creatinine (umol/L)92 (74--118)67 (56--85) \< 0.0001 Haemoglobin (g/L)131 ± 23140 ± 150.003 BNP (ng/L)117 (51--244)33 (24--44) \< 0.0001 NTpro-ANP (pg/ml)6321 (3874)4246 (3402--4532) \< 0.0001Values are mean ± SD, n (%) or median, interquartile range. The p values are for the t test or chi-square test*BNP* B-type natriuretic peptide, *COPD* chronic obstructive pulmonary disease, *HF* heart failure, *HFpEF* heart failure with preserved ejection fraction, *NA* not applicable, *NTpro-ANP* N-terminal pro-atrial natriuretic peptide, *NYHA* New York Heart Association class, *6MWT* six minute walk testTable 2Baseline imaging characteristicsHFpEF\
n = 97Controls\
n = 39p valueCMR LV parameters LVEF (%)56 ± 558 ± 50.058 LVEDVI (ml/m^2^)79 ± 1883 ± 140.237 LVESVI (ml/m^2^)35 ± 1035 ± 80.950 LV mass indexed (g/m^2^)52 ± 1546 ± 100.003 LV mass/LVEDV0.68 ± 0.160.57 ± 0.09 \< 0.0001 LV tissue characterisation  Presence of MI (%)13 (13)0 (0)0.007  MI size (% of LV mass)3.0 (0.9--4.9)NA--  Presence of non-MI focal fibrosis (%)38 (39)5 (13)0.007  Non-MI fibrosis size (% of LV mass)2.8 (1.2--6.6)2.4 (0.6--3.6) \< 0.0001  ^a^Native myocardial T1 (ms)1230 ± 781191 ± 980.038  ^a^Post-contrast myocardial T1 (ms)457 ± 61489 ± 930.007  ^a^ECV (%)28 ± 526 ± 30.008  ^a^iECV (ml/m^2^)14 ± 411 ± 30.001CMR LA parameters Overall---all subjects including atrial fibrillation  SAX LAV max (ml)120 ± 5088 ± 21 \< 0.0001  SAX LAV min (ml)84 ± 4947 ± 14 \< 0.0001  SAX LAEF (%)34 ± 1347 ± 8 \< 0.0001  Biplane LAV max (ml)102 ± 4462 ± 22 \< 0.0001  Biplane LAV min (ml)71 ± 4431 ± 14 \< 0.0001  Biplane LAEF (%)34 ± 1651 ± 11 \< 0.0001 Sinus  SAX LAV max (ml)103 ± 3388 ± 210.004  SAX LAV min (ml)64 ± 2647 ± 14 \< 0.0001  SAX LAEF (%)39 ± 1047 ± 8 \< 0.0001  Biplane LAV max (ml)88 ± 3262 ± 22 \< 0.0001  Biplane LAV min (ml)53 ± 2531 ± 14 \< 0.0001  Biplane LAEF (%)41 ± 1251 ± 11 \< 0.0001 Atrial fibrillation  SAX LAV max (ml)175 ± 56NA--  SAX LAV min (ml)148 ± 51NA--  SAX LAEF (%)16 ± 8NA--  Biplane LAV max (ml)147 ± 45NA--  Biplane LAV min (ml)129 ± 43NA--  Biplane LAEF (%)14 ± 9NA--*ECV* extracellular volume, *iECV* indexed to body surface area; extracellular volume, *LA* left atrium, *LAEF* left atrial ejection fraction, *LAV max* maximal left atrial volume, *LAV min* minimal left atrial volume, *LV* left ventricle, *LVEDVI* left ventricular end-diastolic volume indexed to body surface area, *LVEF* left ventricular ejection fraction, *LVESVI* left ventricular end-systolic volume indexed to body surface area, *MI* myocardial infarction^a^Available in n = 72 HFpEF, n = 35 controls

Biplane LA measures correlated strongly with SAX parameters overall (LAV max Pearson's r = 0.910, LAV min r = 0.884, LAEF r = 0.851), in sinus rhythm (LAV max 0.926, LAV min r = 0.920, LAEF r = 0.651) and moderate to good in AF (LAV max r = 0.776, LAV min r = 0.788, LAEF r = 0.882); p \< 0.0001 for all. LA volumes calculated from the biplane method (excluding the LA appendage) were significantly lower compared to the SAX method overall and irrespective of whether subjects were in sinus rhythm or AF (Table [2](#Tab2){ref-type="table"}). While overall agreements for LA volumes were good (Table [3](#Tab3){ref-type="table"}), the limits of agreement were wider in AF. Biplane LAEF did not differ significantly compared to SAX LAEF except in AF subjects in whom biplane LAEF was comparably lower (mean difference 2 ± 4%, p = 0.013). Intra-observer agreements for both methods were excellent, albeit biplane measures fared slightly worse (Table [4](#Tab4){ref-type="table"}).Table 3Inter-technique agreements for left atrial volumes and ejection fraction between CMR short-axis and biplane methodsParameterCMR SAX mean ± SDCMR biplane Mean ± SDMean dfference ± SD95% Limits of agreementP valueAll patients (n = 97) LAV max (ml)120 ± 50102 ± 4418 ± 21− 22 to 60\< 0.0001 LAV min (ml)84 ± 4971 ± 4413 ± 18− 22 to 48\< 0.0001 LAEF (%)34 ± 1334 ± 16− 1 ± 8− 17 to 150.307Sinus rhythm (n = 74) LAV max (ml)103 ± 3388 ± 3215 ± 13− 9 to 41\< 0.0001 LAV min (ml)64 ± 2653 ± 2511 ± 10− 9 to 31\< 0.0001 LAEF (%)39 ± 1041 ± 12− 2 ± 9− 20 to 160.083Atrial fibrillation (n = 23) LAV max (ml)176 ± 56147 ± 4527 ± 35− 42 to 970.001 LAV min (ml)148 ± 51129 ± 4319 ± 32− 43 to 810.008 LAEF (%)16 ± 814 ± 92 ± 4− 6 to 100.013Abbreviations are as for Table [2](#Tab2){ref-type="table"}Table 4Intra-observer assessments for left atrial volumes and ejection fractionParameterObserver 1\
Mean ± SDObserver 2\
Mean ± SDMean difference ± SDICCVariability (1---ICC)Co-efficient of variation95% Limits of agreementIntra-observer SAX  LAV max (ml)123 ± 40122 ± 391 ± 30.990.013− 7 to 5  LAV min (ml)85 ± 4484 ± 431 ± 20.990.012− 4 to 3  LAEF (%)34 ± 1434 ± 140 ± 20.990.016− 4 to 4 Biplane  LAV max (ml)99 ± 48101 ± 492 ± 50.990.014.8− 7 to 12  LAV min (ml)70 ± 4571 ± 441 ± 40.990.015.4− 7 to 8  LAEF (%)33 ± 1333 ± 130.1 ± 30.980.029.4− 6 to 6Abbreviations are as for Table [2](#Tab2){ref-type="table"}*ICC* intra-class correlation coefficient

Forty four composite events (45%, 25 deaths, 19 HF hospitalizations) were observed in the HFpEF group during median follow-up of 1429 days (1157--1657). Sixteen parameters were associated with outcomes during Cox regression analysis, including both biplane and SAX LAEF (Table [5](#Tab5){ref-type="table"}). Urea and extracellular volume (ECV) were excluded from regression analysis due to collinearity. On Cox regression analysis (Table [6](#Tab6){ref-type="table"}), both biplane and SAX LAEF remained significantly associated with outcome in 3 separate models incorporating clinical factors, biochemical markers and imaging parameters. In a final model comprising the strongest predictors overall, biplane LAEF (HR 0.604; 95% confidence interval \[CI\] (0.406--0.900); p = 0.013) and SAX LAEF (HR 0.636; CI 0.441--0.918; p = 0.016) remained independent predictors along with indexed extracellular volume (iECV). Irrespective of methodology, a lower LAEF group (below median) was associated with increased risk of the composite endpoint (biplane Log-Rank p \< 0.0001; SAX Log-Rank p = 0.009); see Fig. [3](#Fig3){ref-type="fig"}. The area under curve for predicting outcomes was higher for SAX LAEF (0.709, p \< 0.0001), albeit not significantly different compared to biplane LAEF (0.690, p = 0.001).Table 5Unadjusted predictors for the composite endpoint of death and/or hospitalization with heart failureUnadjusted predictors of outcomeHazard ratio (95%CI)P valueClinical Age (years)1.630 (1.203--2.210)0.002 Average diastolic BP (mmHg)0.562 (0.388--0.814)0.002 Prior HF hospitalization2.236 (1.104--4.529)0.025 6MWT distance (m)0.545 (0.339--0.876)0.012Clinical blood samples ^a^Urea (mmol/L)1.284 (1.002--1.644)0.048 Log creatinine (umol/L)1.352 (1.024--1.784)0.033 Haemoglobin (g/L)0.766 (0.576--1.019)0.067 Log BNP (ng/L)1.542 (1.086--2.189)0.016 NTpro-ANP (pg/ml)1.551 (1.113--2.160)0.009Imaging (CMR) LV mass index (g/m^2^)1.432 (1.020--2.010)0.038 LAVI max (ml/m^2^)1.595 (1.202--2.115)0.001 LGE MI (%)1.687 (0.784--3.632)0.181 ^a^ECV (%)1.822 (1.173--2.831)0.008 iECV (ml/m^2^)1.558 (1.097--2.213)0.013 Biplane LAEF (%)0.575 (0.419--0.788)0.001 SAX LAEF (%)0.596 (0.447--0.794)0.0001Abbreviations are as for Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}; Hazard ratios are based upon one standard deviation increase in the predictor variable for continuous variables which are Z-standardized*CI* confidence interval; *LAVI max* left atrial maximal volume indexed to body surface area^a^Parameters not entered into multivariable analysisTable 6Multiple Cox regression models inclusive of biplane and SAX LAEF for the composite endpoint of death and/or hospitalization with heart failureCox proportional hazard regression predictors of outcomeIncluding biplane LAEFIncluding SAX LAEFHazard ratio (95%CI)P valueHazard ratio (95%CI)P valueClinical Age1.126 (0.771--1.645)0.538Age1.049 (0.708--1.555)0.811 Average diastolic BP0.606 (0.407--0.904)0.014Average diastolic BP0.580 (0.390--0.863)0.007 Prior HF hospitalization1.693 (0.810--3.540)0.162Prior HF hospitalization1.588 (0.754--3.347)0.224 6MWT distance0.596 (0.372--0.956)0.0326MWT distance0.613 (0.387--0.972)0.038** + Biplane LAEF**0.535 (0.385--0.744) \< 0.0001** + SAX LAEF**0.532 (0.391--0.724) \< 0.0001Clinical blood samples Log creatinine (umol/L)1.035 (0.731--1.466)0.0847Log creatinine (umol/L)1.033 (0.734--1.454)0.853 Haemoglobin (g/L)0.805 (0.584--1.109)0.155Haemoglobin (g/L)0.677 (0.496--0.923)0.114 Log BNP (ng/L)1.126 (0.712--1.782)0.611Log BNP (ng/L)1.128 (0.712--1.787)0.607 Log NTpro-ANP1.373 (0.990--1.906)0.058NTpro-ANP1.244 (0.890--1.739)0.202** + Biplane LAEF**0.649 (0.456--0.924)0.016** + SAX LAEF**0.552 (0.410--0.741) \< 0.0001Imaging LV mass index0.582 (0.217--1.560)0.282LV mass index0.529 (0.205--1.366)0.188 LAVI max0.961 (0.599--1.541)0.869LAVI max0.997 (0.630--1.577)0.988 iECV1.558 (1.097--2.213)0.013iECV1.564 (1.106--2.211)0.011** + Biplane LAEF**0.575 (0.419--0.788)0.001** + SAX LAEF**0.668 (0.472--0.944)0.022Strongest markers combined Average diastolic BP0.723 (0.461--1.134)0.158Average diastolic BP0.725 (0.461--1.139)0.163 6MWT distance0.611 (0.354--1.053)0.0766MWT distance0.592 (0.346--1.011)0.055 iECV1.491 (1.038--2.143)0.031iECV1.584 (1.110--2.260)0.011** + Biplane LAEF**0.604 (0.406--0.900)0.013** + SAX LAEF**0.636 (0.441--0.918)0.016Fig. 3Survival analysis stratified according to median left atrial ejection fraction. Kaplan--Meier analysis stratified according to median left atrial ejection fraction for the composite endpoint of death and/or hospitalization with heart failure using the biplane method (left panel) and the short-axis method (right panel)

Discussion {#Sec4}
==========

Our study is the first to compare the agreements of both CMR biplane and SAX LAEF in HFpEF and assess their prognostic capabilities in the same setting. Our results confirm LAEF as an independent marker of prognosis in HFpEF, irrespective of CMR technique and validate our earlier findings of biplane LAEF as a strong prognostic biomarker \[[@CR1]\]. The ability of CMR LAEF to be measured via 2 separate methods with a high degree of precision and reproducibility in addition to its prognostic capabilities are important strengths for consideration when being proposed as an imaging biomarker \[[@CR6]\]. While CMR SAX LAEF is considered the more accurate of both measures \[[@CR2], [@CR3]\], the CMR biplane method represents a potentially useful alternative for both research and clinical settings in HFpEF and has been recently proposed as the preferred method of LA volumetric analysis in an expert consensus document by the European Association of Cardiovascular Imaging \[[@CR7]\]. Biplane LAEF derivation does not necessitate additional, multiple short axis image acquisitions which can prolong scan times in predominantly elderly subjects typical of HFpEF, who may struggle with multiple breath-holds. Furthermore, image analysis of the biplane method is also significantly shorter. On the other hand, SAX LAEF is an alternative if long axis images are degraded by artefact. Our findings are also important since LAEF represents a potential therapeutic target in HFpEF \[[@CR8]\] where there are currently no effective therapies \[[@CR9]\] and may also act as a trial endpoint \[[@CR10]\].

While LA volumes were underestimated by the biplane method compared to SAX evaluation, LAEF did not differ significantly except in AF. Since LAEF is a fraction derived from volumetric analysis, systematic bias of similar magnitudes in the same direction i.e. underestimation of both LAV max and LAV min likely explains this lack of LAEF difference between both the techniques. The difference in LA volumes between both methods however is unsurprising given that the LA appendage is typically excluded from the biplane method but included in the SAX method \[[@CR2], [@CR3]\]. These volumetric differences are likely further exaggerated in HFpEF where LA dilation is typical \[[@CR2], [@CR4]\] and associated with a higher prevalence of AF. Furthermore, in AF we employed prospective gating which can lower the margins for erroneous measurements. As addressed in our recent publication, we also recognise that having some subjects with hypertension in our control group is a limitation given that these subjects were not totally free from cardiovascular disease. However, LAEF was again lower in HFpEF with either methodology, irrespective of controls' hypertensive status, reinforcing altered LA contractile function in the pathophysiology of HFpEF.

Conclusions {#Sec5}
===========

CMR LAEF calculated from either the short-axis or biplane method has excellent reproducibility and remains a strong marker of prognosis in HFpEF.
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